Abstract
• Introduction
. This paved the way for the first successful clinical transplantation of a fully tissue-engineered organ, where a donor trachea was first decellularized by using a detergent (without denaturing the collagenous matrix), recellularized in a bioreactor that reseeded the recipients' MSC-derived chondrocytes cells on the outer and respiratory epithelial cells on the inner surfaces of the scaffold, and then implanted (Fig. 1) .
The purpose of this review is to provide an overview of the methods used to obtain bioengineered tracheal scaffolds and discuss future directions and potential synergies between recent scientific advances and regulations with the ultimate goal for safe, effective and worldwide regeneration of functional airway. Belsey [6] 
Rationales for tracheal transplantation

Today, the vast majority of benign or malignant tracheal lesions can be resected and primary reconstruction is safely carried out by end-to-end anastomosis. Unfortunately, when the disease length extends to more than 50% of the total (in adults) or one third (in small children) tracheal length, safe reconstruction is impossible and a tracheal replacement desirable. According to
Historical background
The apparent simplicity of the trachea encouraged investigations lasting a century, with tubular tracheal replacement using different potential substitutes like prosthetic materials, auto-and allografts [2] . Solid [11] and that the human tracheal epithelium display HLA-DR antigens that activate T lymphocytes and thereby trigger graft rejection [12, 13] [2] . Allotransplantation of pre-irradiated tracheal grafts, without immunosuppressive drugs, is feasible only using high radiation doses and indirect omentum major vascularization [14] . Chemically treated tracheas, implanted as auto-, allo-or xenografts, do not induce any rejection, but no cartilage and epithelium development was reported [15] . Implanted cadaveric formalin fixed allografts showed reduced allogenicity and complete epithelization, but required frequent bronchoscopies to remove exuberant granulation tissue and ultimately became completely malacic [16, 17] . Cryopreservation has been demonstrated to have an immunomodulatory effect on several tissues resulting in the loss of class II HLA-antigen expression during freezing and thawing [18] [19] [20] . It has been suggested that a long period of cryopreservation, increasing the degree of degeneration in both epithelium and cartilage and reducing chondrocytes viability, may help to maintain a better patency of tracheal allografts by preventing an allogenic response [21, 22] . Transplantation of cryopreserved trachea allowed to preserve well the epithelium function and histological characteristics, but cartilaginous ischemic changes occurred [23] [24] [25] , probably due to a slow and inadequate revascularization with insufficient graft blood supply consequently. It has been, indeed, demonstrated that only revascularized, cryopreserved allografts inhibited allogenicity and maintained structural functionality and integrity [26] [27] [28] [57] [58] [59] . Moreover, the use of growth factors in MSC expansion medium, prior differentiation, has been shown to have a significant effect on the ability of human MSCs to undergo chondrogenesis [52, 53, 60, 61] . [62] , using a highdensity pellet culture of MSCs. The Hollander group has recently described methods for consistent growth of MSCs using bFGF to minimize variability between patients [63] and parathyroid hormone related protein to prevent terminal hypertrophic differentiation of MSC-derived chondrocytes [64] [1, 65] . [84] . The doublechamber bioreactor allows obtaining expansion and migration on the scaffold of two autologous cell types with different media requirement, to maintain construct oxygenation despite the thickness of the implant wall, to properly re-personalize a donor trachea and to successfully perform the first engineered airway transplantation without the need of any immunosuppressive therapy [1] . The bioreactor could eventually be further optimized to improve safety, standardization and traceability of the whole process (with a complete automation of the system), promote orientated ciliary function (with flow stimuli to the internal bioreactor compartment) and trigger angiogenesis (with radial-flow pressurized liquid perfusion inside the scaffold). Presently, we are evaluating a further bioreactor technology that previously has been successfully developed for automation and GMP processes in liver cells regeneration [75] -it allows simultaneous air and liquid perfusion and has been optimized for sterile handling in a clinical environment [76] . This bioreactor has been tested in a number of preclinical and clinical applications, especially in the cardiovascular field (heart valve and vessel), and recently also for a tracheal preparation process, providing GMP conditions for implant manufacture (Fig. 4) . (Fig. 5) . The product is not the implant, but the process to make the implant as part of a therapy. This is the safest methodology existing with respect to avoiding transformation, infectious risks and increasing quality. The scaffold must be such to be able to react to remodelling stimuli and ideally all is prepared using fully closed GMP compliant one-way devices [79, 75, 92] 
Human tissue engineering tracheal replacement
The traditional method to generate a human tissue-engineered trachea bases on three key components: (i ) a human donor trachea decellularized via a DEM, (ii) autologous cells (MSCderived chondrocytes and epithelial cells) and (iii) a specific designed bioreactor that reseeds the autologous cells on the
TGF-␤ induction of a controlled differentiation of MSCs to chondrocytes was first described by Johnstone
Epithelial respiratory cells
Fig. 5 Bionic concept towards worldwide tissue-engineered tracheal replacement. The retrieved human tracheas are kept at -4ЊC and can be stored up to 11 months. Operations can be made as an elective procedure and purely intraoperatively (eliminating the need of human cell transportation, manipulation): a bone marrow aspiration of 30 to 60 ml needs to be centrifugated and then seeded on the tracheal matrix, without any further cell manipulation (thereby it will not be a cell therapy nor and advanced therapy). The own patient's stem cells can be activated, controlled and induced to differentiation and proliferation by means local and systemic recruitment, boosting, permissive and commitment factors. media with high concentration of retinoic acid and Ca 2ϩ levels induced a pseudo-stratified differentiation of primary epithelial cell cultures [71]. However in the study, no key factor in the composition of the partially defined media could be identified. Recently, Pfenninger et al. [72] suggested that (i ) a basal lamina-equivalent of collagen fibres, (ii ) extracellular factors secreted by fibroblasts and (iii ) the creation of an air-liquid interface systems are the three key factors necessary to induce epithelial cells differentia-
Ongoing progress
